Axitinib Poised To Join Pfizer's RCC Drug Portfolio In 2012
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer's second generation VEGF inhibitor axitinib for advanced renal cell carcinoma has been granted a standard, 10-month review by FDA.